2023-509915-10-00CompletedPhase 1
A Phase I Study of Belantamab Mafodotin in Multiple Myeloma Participants with Normal and Impaired Hepatic Function
Source: EU CTIS (euclinicaltrials.eu) · Last updated 20 Mar 2025
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 8 (actual)
- First submitted
- 26 Jan 2024
- Start date
- 27 Jul 2021
- Lead sponsor
- Glaxosmithkline Research & Development Limited
- Diseases
- Multiple myeloma
- EU CT number
- 2023-509915-10-00
- EudraCT number
- 2021-001720-18
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 8
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (2)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Evangelismos S A | Athens | Greece | Completed |
| Alexandra Hospital | Athens | Greece | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.